CEVEC Raises €6M to Grow CAP® Technol. Based Protein & Vaccine Business

Cologne, Germany, July 25, 2011 / B3C newswire / - CEVEC Pharmaceuticals, licensing its human CAP® Technology based expression system for proteins and vaccines, today announced the closing of a €6M financing round. NRW.BANK and Creathor Venture Fonds led this round which included the participation from current investors, a group of private and institutional investors and ERP Startfonds of KfW bank.The funding enables CEVEC to strengthen the growth of its protein and vaccine commercialization business of the proprietary CAP® Technology platform. CEVEC also intends to develop certain vaccines together with partners based on a further financing round, to be closed by the end of 2011.

The CAP® Technology platform comprises human CAP® and CAP-T™ expression systems and is used for the manufacture of complex biologics and therapeutic antibodies with human-like glycosylation and sialylation patterns. New data proved that the human CAP® technology is also an excellent platform for various vaccine production needs. Outstanding data obtained with the only independent available human cell system for various influenza strains and various other vaccine types show the broad range where the CAP system can be used.

Dr. Rainer Lichtenberger, CEO of CEVEC comments: “We are delighted for having the financial resources to making the human CAP technology the leading system in the global expression market. With Creathor Venture and NRW.BANK we have two first-class investors on board who value the unique strengths of our CAP® Technology.”

Wolfgang Kintzel, CCO of CEVEC states: “After the successful launch of CAP® und CAP-T™ in Europe, Asia/Pacific and the U.S. for use in the field of protein and antibody expression, the new excellent scientific data using the system for vaccine production open a truly outstanding new business opportunity for CEVEC. The human CAP technology will soon become the leading cell line for all vaccine and protein production needs.”

Karlheinz Schmelig, Chairman of CEVEC´s supervisory board and Managing Director at Creathor Venture and Dr. Aristotelis Nastos, NRW.BANK, add: “We see tremendous commercial opportunities for customers and CEVEC in the global pharmaceutical manufacturing markets with CEVEC’s high performance human expression system CAP. We also highly value the outstanding management and scientific team of CEVEC and their proven execution skills.”

About CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH, operational since 2004 and located in Cologne, Germany, is a biopharmaceutical company that specializes in developing and producing therapeutic proteins, vaccines and monoclonal antibodies with human glycosylation patterns. CEVEC’s novel proprietary and patent-protected human CAP® and CAP-T ™ expression systems are ideal for manufacturing complex biopharmaceutical molecules and various vaccines. CEVEC is licensing out its human cell-based expression platform as well as its own Biobetter Candidates through partnerships with renowned pharmaceutical and biotech companies.

About Creathor Venture

CREATHOR VENTURE invests in technology-oriented companies and entrepreneurs from the fields of life science, IT, telecommunication, new media, new materials, electronics, nanotechnology and clean tech.
CREATHOR VENTURE’s management team includes Dr. Gert Köhler, the founder of the former Technologieholding VC GmbH, as well as Ingo Franz and Karlheinz Schmelig. The team has been working in early-stage venture capital for 20 years. During that time more than 200 technology companies have been financed and over 20 IPOs as well as numerous trade sales have been conducted.
Extraordinarily successful companies that the partners have managed from the first round of financing to IPO include Micronas (SMI), SEZ (SMI), Intershop (Prime Segment), Infovista (NASDAQ, Nouveau Marché) and ITN Nanovation (Prime Segment).

About NRW.BANK

NRW.BANK is the state development bank of North Rhine-Westphalia (NRW). Its mission is to support its owners - the state of North Rhine-Westphalia as well as the Regional Associations of Westphalia-Lippe and the Rhineland - in the completion of important structural policy tasks. Headquartered in Düsseldorf and in Münster, the Bank supports the regional economy, the municipalities and the people of NRW with the full range of credit products from the development programs of the state, the federal government and the EU to equity and debt financing alternatives.

For business start-ups and SMEs in North Rhine-Westphalia, NRW.BANK uses customized public promotion and equity finance products. The Bank aims to constantly improve the financing situation of this target group. For this purpose NRW.BANK has aligned its equity capital products with companies’ lifecycles and their resulting requirements.


Contact:
Wolfgang Kintzel
Chief Commercial Officer / Geschäftsführer
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Straße 62
D-51105 Köln
Germany
fon +49 (0) 221-46 02 08 - 00
fax +49 (0) 221-46 02 08 – 01

kintzel@cevec.com

CEVEC and Catalent Pharma Solutions Offer Joint Cell Line Development Service

Cologne, Germany, June 16, 2011 / B3C newswire / – CEVEC Pharmaceuticals, the German developer of a novel, market leading human protein expression system derived from amniocytes, and Catalent Pharma Solutions, a leading global drug development and delivery solutions provider, announced today a joint commercial cell line development service for pharma and biotech customers worldwide.

The offering combines the benefits of CEVEC’s human cell line, CAP-Technology, with Catalent’s unique GPEx® (Gene Product Expression) Technology to generate high expressing stable human cell lines in a much shorter time frame than traditional methods.

“We are very pleased to be working with Catalent and their truly unique technology to generate stable lines“ said Dr. Rainer Lichtenberger, CEO of CEVEC. “Several months of testing convincingly showed combining CAP cells and GPEx technology is a very powerful approach. We achieved yields exceeding 3 g/L for a very complex protein produced in our human production cell lines in a very short time frame” added Wolfgang Kintzel, Managing Director and CCO of CEVEC. “The combined offering is a very compelling value proposition for clients looking to outsource cell line development and potential downstream cGMP upscaling while looking for the highest quality using a human cell line.”

“Catalent has been collaborating with customers and suppliers to accelerate biologics development for more than ten years. This exciting collaboration with CEVEC will offer biotech companies developing recombinant proteins and antibodies the advantage of two technologies in one system, enabling them to get a clone candidate in less than 5 months and significantly reducing their time to clinic” stated Scott Houlton, President, Development & Clinical Services. “The GPEx technology has been used to express more than 380 different molecules and our integrated development and manufacturing services allow us to take our customers through their clinical trials in the fastest, most cost effective manner.”

For more information regarding GPEx® technology and Catalent’s biologics offering, please visit Catalent’s web site at www.catalent.com.

About Catalent Pharma Solutions

From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 8,000 people at 24 facilities worldwide and in fiscal year 2010 generated more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, NJ, USA.

Catalent. more products. better treatments. reliably supplied.™

About CEVEC Pharmaceuticals GmbH

CEVEC Pharmaceuticals GmbH, operational since 2004 was founded by a group of internationally renowned scientists and clinicians from the University of Cologne. Based on their experience and their longstanding collaborative work, they had perceived a lack of innovative expression systems for more efficient production of biologics such as recombinant proteins or gene therapy vectors. CEVEC’s novel proprietary human CAP® and CAP-T® expression systems are ideal for manufacturing complex and difficult to express biopharmaceutical molecules with authentic human glycosylation patterns. CEVEC´s CAP technology is becoming also the gold standard for various vaccines production approaches. The immortalized cells are derived from primary human amniocytes and meet highest ethical standards. Already adapted to serum-free growth conditions, they can be very efficiently transfected with commercially available transfection reagents and are optimized to grow in a variety of flask/wave formats up to large-scale processing in bioreactors. CAP® and CAP-T® are trademarks of CEVEC Pharmaceuticals GmbH, all rights reserved, CAP-T® not yet registered in all territories.

Contact

Wolfgang Kintzel

CCO / Geschäftsführer

CEVEC Pharmaceuticals GmbH

Gottfried-Hagen Straße 62

D-51105 Köln

Germany

Tel. : +49 (0) 221-46 02 08 - 00

Fax: +49 (0) 221-46 02 08 - 01

kintzel@cevec.com

 

Sven Lee

VP Business Development Biologics

Catalent Pharma Solutions

8137 Forsythia St

Middleton, WI 53562

USA

Tel: +1 303-841-3923

sven.lee@catalent.com
 

Changes in CEVEC’s Supervisory Board

Cologne, Germany, December 21, 2010 / b3c newswire / – CEVEC Pharmaceuticals, the developer of the CAP® protein expression system derived from human amniocytes, today announced that Rainer Christine has joined its supervisory board.

Rainer Christine was the CEO and co-founder of the German-American biotools company amaxa and plays an active role in the life sciences related venture capital industry.

Under Rainer’s leadership amaxa grew from start-up in 1998 to a full-fledged and profitable life science company with strong scientific and commercial activities, 160 staff in Europe and the US, and more than EUR 100 million in cumulative sales. In 2008, amaxa was successfully sold to Lonza, a global supplier to the life-science industry.

At the same time, Gangolf Ehlen, previous Chairman of CEVEC’s supervisory board and lead investor from Venture Capital Beteiligungen Sparkasse KölnBonn, will resign from the CEVEC board to pursue a new role at Sparkasse KölnBonn. New chairman of the board will be the current vice-chairman Karlheinz Schmelig, Managing Partner at current lead investor Creathor Venture.

„CEVEC is delighted to have secured the services of Rainer Christine. With his experience and recognition as a high-profile Life Sciences entrepreneur he joins as a very valuable addition to our board“ stated Rainer Lichtenberger, Managing Director / CEO of CEVEC . Wolfgang Kintzel, Managing Director / CCO added: „We are also extremely grateful to Gangolf Ehlen for his outstanding commitment for CEVEC over the last years and wish him all the best for his new assignment at Sparkasse KölnBonn.“

The CEVEC supervisory board changes are accompanied by the successful first closing of a further financing round to expand CEVECs vaccine platform business.

CAP® cells are a human immortalized cell line derived from primary human amniocytes. CAP® cells grow in serum-free suspension cultures, allow for stable protein production and show human-like post-translational modifications including authentic human glycosylation patterns.

CAP® is a trademark of CEVEC Pharmaceuticals GmbH, all rights reserved.

About CEVEC Pharmaceuticals GmbH - www.cevec-pharmaceuticals.com
CEVEC Pharmaceuticals GmbH, operational since 2004 was founded by a group of internationally renowned scientists and clinicians from the University of Cologne. Based on their experience and their longstanding collaborative work, they had perceived a lack of innovative expression systems for more efficient production of biologics such as recombinant proteins or gene therapy vectors. CEVEC’s novel proprietary human CAP® and CAP-T® expression systems are ideal for manufacturing complex and difficult to express biopharmaceutical molecules with authentic human glycosylation patterns. The immortalized cells are derived from primary human amniocytes and meet highest ethical standards. Already adapted to serum-free growth conditions, they can be very efficiently transfected with commercially available transfection reagents and are optimized to grow in a variety of flask/wave formats up to large-scale processing in bioreactors. CEVEC offers flexible licensing arrangements for CAP® and CAP-T®. Additionally, co-development opportunities are available for selected complex therapeutic proteins made with the CAP-T® technology to address attractive target markets.

Contact

Wolfgang Kintzel
CCO / Geschäftsführer
CEVEC Pharmaceuticals GmbH

Gottfried-Hagen Straße 62
D-51105 Köln
Germany

Tel. : +49 (0) 221-46 02 08 - 00
Fax: +49 (0) 221-46 02 08 - 01

kintzel@cevec-pharmaceuticals.com


 

CEVEC Pharmaceuticals Opens US Subsidiary

Cologne, Germany, November 15, 2010 / b3c newswire / - CEVEC Pharmaceuticals, the developer of a novel human protein expression system derived from amniocytes, announced today the US expansion of it’s business by founding a North American subsidiary, CEVEC Pharmaceuticals, Inc., in Potomac, Maryland, USA.

Located close to Washington DC and amidst the Northeast US Bioscience Corridor, the incorporation of the new site reflects CEVEC ambition to better serve the growing US market.

„The largest global Life Science market is the United States“ stated Dr. Rainer Lichtenberger, CEO of CEVEC. „ Since we have now a significant number of license holders based in the US, the new expansion will allow us to provide high quality, fast and very focused customer service".

Wolfgang Kintzel, CCO of CEVEC added: „Gary Boch, VP Business Development, North America, a very experienced Life Science professional, will manage our US business. From Maryland (US) we will now have the chance to further establish the CAP technology as a key protein expression platform being closer to our key customers and business partners.“

CAP® cells are a human immortalized cell line derived from primary human amniocytes that meet highest ethical standards. CAP® cells grow in serum-free suspension cultures, allow stable protein production, and show human-like post-translational modifications and authentic human glycosylation patterns.

CAP® is a trademark of CEVEC Pharmaceuticals GmbH, all rights reserved.


About CEVEC Pharmaceuticals GmbH - www.cevec-pharmaceuticals.com
CEVEC Pharmaceuticals GmbH, operational since 2004 was founded by a group of internationally renowned scientists and clinicians from the University of Cologne. Based on their experience and their longstanding collaborative work, they had perceived a lack of innovative expression systems for more efficient production of biologics such as recombinant proteins or gene therapy vectors. CEVEC’s novel proprietary human CAP® and CAP-T® expression systems are ideal for manufacturing complex and difficult to express biopharmaceutical molecules with authentic human glycosylation patterns. The immortalized cells are derived from primary human amniocytes and meet highest ethical standards. Already adapted to serum-free growth conditions, they can be very efficiently transfected with commercially available transfection reagents and are optimized to grow in a variety of flask/wave formats up to large-scale processing in bioreactors. CEVEC offers flexible licensing arrangements for CAP® and CAP-T®. Additionally, co-development opportunities are available for selected complex therapeutic proteins made with the CAP-T® Technology to address attractive target markets.

Contact

Wolfgang Kintzel
CCO / Geschäftsführer
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Straße 62
D-51105 Köln
Germany
Tel. : +49 (0) 221-46 02 08 - 00
Fax: +49 (0) 221-46 02 08 - 01
kintzel@cevec-pharmaceuticals.com
 

CAP Cells Suitable For Commercial Vaccine Production?

Cologne, Germany, September 28, 2010 / b3c newswire / – CEVEC Pharmaceuticals, the developer of an extremely potent protein expression system based on human CAP cells, announced today that CAP cells produce high virus titers upon infection with influenza strains. The virus titers are as good as or even higher than with MDCK and Vero cells, host cells currently used for influenza vaccine production.

The data were obtained in a collaborative project with Prof. Dr. Reichl at the Max-Planck-Institute for Dynamics of Complex Technical Systems in Magdeburg, an internationally renowned expert for design and optimization of vaccine production processes in Germany.

CAP cells were infected with various human, equine and swine influenza strains and the virus titers compared to MDCK suspension cells.

“CAP cells could prove to be of significant advantage for the production of flu vaccines,” said Dr. Rainer Lichtenberger, CEO of CEVEC. “The achieved virus yields give hope for a more efficient production than with the help of conventional egg-based technology.”

“The infected CAP cells grow rapidly in serum-free and commercially available media. With an optimized medium even higher virus titers can be expected,” added Wolfgang Kintzel, CEVEC’s Chief Commercial Officer and Managing Director.

"The human suspension cell line CAP has an enormous potential for establishment of state-of-the-art influenza vaccine manufacturing processes," said Prof. Reichl from the Max-Planck Insitute in Magdeburg.

CAP is the last independent human cell line for the production of vaccines and recombinant proteins.

CAP cells are a human immortalized cell line derived from primary human amniocytes that meet highest ethical standards. CAP cells grow in serum-free suspension cultures, allow stable protein production, and show human-like post-translational modifications and authentic human glycosylation patterns.

CAP® is a trademark of CEVEC Pharmaceuticals GmbH, all rights reserved,



About CEVEC Pharmaceuticals GmbH - www.cevec-pharmaceuticals.com
CEVEC Pharmaceuticals GmbH, operational since 2004 was founded by a group of internationally renowned scientists and clinicians from the University of Cologne. Based on their experience and their longstanding collaborative work, they had perceived a lack of innovative expression systems for more efficient production of biologics such as recombinant proteins or gene therapy vectors. CEVEC’s novel proprietary human CAP® and CAP-T® expression systems are ideal for manufacturing complex and difficult to express biopharmaceutical molecules with authentic human glycosylation patterns. The immortalized cells are derived from primary human amniocytes and meet highest ethical standards. Already adapted to serum-free growth conditions, they can be very efficiently transfected with commercially available transfection reagents and are optimized to grow in a variety of flask/wave formats up to large-scale processing in bioreactors. CEVEC offers flexible licensing arrangements for CAP and CAP-T. Additionally, co-development opportunities are available for selected complex therapeutic proteins made with the CAP Technology to address attractive target markets.

Contact

Wolfgang Kintzel
CCO / Geschäftsführer
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Straße 62
D-51105 Köln
Germany
Tel. : +49 (0) 221-46 02 08 - 00
Fax: +49 (0) 221-46 02 08 - 01
kintzel@cevec-pharmaceuticals.com

CEVEC Signs Global License Agreement for CAP-T with Life Technologies

Cologne, Germany, August 18, 2010 / b3c newswire / – CEVEC Pharmaceuticals, the developer of a novel human protein expression system derived from amniocytes, announced today the signing of a co-exclusive worldwide licensing agreement with Life Technologies Corporation, a leading provider of innovative life science solutions based in Carlsbad, California.

Under the terms of the agreement, Life Technologies and CEVEC will co-operate to offer optimized expression kits based on CEVEC’s proprietary CAP-T cells to the global life science research community. Life Technologies will pay CEVEC a signing fee and various milestone payments and royalties on sales of the future products. Further details of the agreement were not disclosed. CEVEC will continue to expand its global license business of the CAP® and CAP-T® technologies for commercial use and industrial development purposes.

CEVEC’s transient CAP-T protein production technology is based on CAP cells, a human immortalized cell line for stable protein production derived from amniocytes. CAP cells are optimized to growth in serum-free suspension cultures and show human-like post-translational modifications including authentic human glycosylation patterns.
Life Technologies combines CEVEC’s proprietary protein expression system based on CAP cells with its tailored protein expression product portfolio (media, transfection reagents etc.) to enable research scientists worldwide to achieve highest yield and quality protein expression.

“We strongly believe in the tremendous value of the co-operation as the global research community is offered a fully optimized human expression system to transiently express proteins with superior yields and authentic human glycosylation patterns,” said Wolfgang Kintzel, CEVEC’s Chief Commercial Officer and Managing Director.

“We are extremely proud that Life Technologies has chosen the CAP technology to extend its top notch protein expression product portfolio,” added Dr. Rainer Lichtenberger, CEO of CEVEC.

The immortalized CAP cells are derived from primary human amniocytes and meet highest ethical standards. CAP cells are optimized to grow in a variety of flask/wave formats up to large-scale processing in bioreactors and can be very efficiently transfected with commercially available transfection reagents.

CAP® and CAP-T® are trademarks of CEVEC Pharmaceuticals GmbH, all rights reserved, CAP-T® not yet registered in all territories.


About CEVEC Pharmaceuticals GmbH - www.cevec-pharmaceuticals.com
CEVEC Pharmaceuticals GmbH, operational since 2004 was founded by a group of internationally renowned scientists and clinicians from the University of Cologne. Based on their experience and their longstanding collaborative work, they had perceived a lack of innovative expression systems for more efficient production of biologics such as recombinant proteins or gene therapy vectors. CEVEC’s novel proprietary human CAP® and CAP-T® expression systems are ideal for manufacturing complex and difficult to express biopharmaceutical molecules with authentic human glycosylation patterns. The immortalized cells are derived from primary human amniocytes and meet highest ethical standards. Already adapted to serum-free growth conditions, they can be very efficiently transfected with commercially available transfection reagents and are optimized to grow in a variety of flask/wave formats up to large-scale processing in bioreactors. CEVEC offers flexible licensing arrangements for CAP and CAP-T. Additionally, co-development opportunities are available for selected complex therapeutic proteins made with the CAP Technology to address attractive target markets.

Contact

Wolfgang Kintzel
CCO / Geschäftsführer
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Straße 62
D-51105 Köln
Germany
Tel. : +49 (0) 221-46 02 08 - 00
Fax: +49 (0) 221-46 02 08 - 01
kintzel@cevec-pharmaceuticals.com This e-mail address is being protected from spambots. You need JavaScript enabled to view it
 

Pevion Biotech and CEVEC Sign Exclusive License Option Agreement

Cologne, Germany, May 26, 2010 / b3c newswire – CEVEC Pharmaceuticals, the German developer of a novel human expression system derived from amniocytes, announced today the signing of an exclusive license option agreement with Pevion Biotech, the Swiss vaccine company.

The agreement enables Pevion Biotech to exclusively use CEVEC’s transient CAP-T cell expression technology to manufacture and commercialize a protein antigen for vaccination against a wide-spread human infectious disease. Following successful entry into toxicological studies and clinical phases I to III, CEVEC will receive undisclosed milestone payments and additional running royalties after market approval. Further financial details of the agreement were not disclosed.

The transient CAP-T protein production technology is based on CAP cells, a human immortalized cell line for stable protein production derived from amniocytes and developed by CEVEC. These non-tumor origin cell lines exhibit high protein expression levels even for difficult to express proteins. They have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns. The platform allows efficient protein production from research, development and scale up to large scale manufacturing in high-volume bioreactors.

„The signing of this agreement is a major milestone for CEVEC since it represents our first exclusively granted license for a clinically highly relevant protein produced in our CAP cells. We’re proud that Pevion Biotech as one of the most innovative vaccine companies has chosen our CAP Technology expression platform to produce a technically demanding protein that so far remains a challenge to be expressed in standard cells like CHO or HEK 293,“ states Rainer Lichtenberger, CEO of Cevec Pharmaceuticals.

The target protein is part of a vaccine that Pevion Biotech intends to develop based on its proprietary and market-validated virosome technology platform.

About CEVEC Pharmaceuticals GmbH

CEVEC Pharmaceuticals GmbH, operational since 2004 was founded by a group of internationally renowned scientists and clinicians from the University of Cologne. Based on their experience and their longstanding collaborative work, they had perceived a lack of innovative expression systems for more efficient production of biologics such as recombinant proteins or gene therapy vectors. CEVEC’s novel proprietary human CAP® and CAP-T™ expression systems are ideal for manufacturing complex and difficult to express biopharmaceutical molecules with authentic human glycosylation patterns.

Contact:
Wolfgang Kintzel
CCO / Geschäftsführer

CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Straße 62
D-51105 Köln
Germany
Tel. : +49 (0) 221-46 02 08 - 00
Fax : +49 (0) 221-46 02 08 - 01
kintzel@cevec-pharmaceuticals.com

CAP and CAP-T are trademarks of CEVEC Pharmaceuticals GmbH, all rights reserved.

Aragen Bioscience, Inc. and CEVEC Pharmaceuticals Sign License Agreement

Cologne, Germany, April 29, 2010 - CEVEC Pharmaceuticals (“CEVEC”), the developer of a novel human expression system derived from amniocytes, and Aragen Bioscience, Inc. (“Aragen Bioscience”), a California based contract research and development organization, announced today the signing of a strategic license agreement.

This license enables Aragen Bioscience to offer its clients custom recombinant human cell lines expressing biotherapeutic proteins and antibodies as well as the transient and stable production of preclinical and clinical grade material.

The transient CAP-T protein production technology is based on CAP cells, an immortalized cell line for stable protein production developed by CEVEC. These non-tumor origin cell lines exhibit high protein expression, have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns.

The collaboration couples CEVEC’s novel and proprietary CAP and CAP-T expression systems and cell lines with Aragen Bioscience’s vast experience in cell line and process development to provide biotechnology and biopharmaceutical companies worldwide the opportunity to utilize Aragen’s services to gain access to CEVEC’s technology and quickly obtain high quality pre-clinical and clinical grade product generated from stable as well as transiently transfected cell lines.

“We are very proud to win Aragen as an experienced and trusted partner to offer our CAP Technology to a broader audience in the Biotechnology and Pharma sector,“ stated Wolfgang Kintzel, CCO of CEVEC. “Our human amniocyte derived cells offer significant advantages when it comes to complex protein production and we’re excited that Aragen has chosen our technology as a valuable addition to their existing service offerings. The signing of this contract also underlines the growing recognition our technology is receiving in the Life Sciences arena.“

Rick Srigley, CEO of Aragen Bioscience said: “We are very excited about the potential of CEVEC's CAP and CAP-T technology. We believe that human cells will be a superior production system for a variety of complex proteins. CEVEC’s technology is a valuable addition to our existing expression portfolio and will enable our customers to pursue new directions for proteins that were difficult to express in the past or did not show satisfactory posttranslational modifications.”

About CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH, operational since 2004 was founded by a group of internationally renowned scientists and clinicians from the University of Cologne. Based on their experience and their longstanding collaborative work, they had perceived a lack of innovative expression systems for more efficient production of biologics such as recombinant proteins or gene therapy vectors. CEVEC’s novel proprietary human CAP and CAP-T expression systems are ideal for manufacturing complex biopharmaceutical molecules with human glycosylation patterns.

About Aragen Bioscience, Inc. - www.aragenbio.com
Aragen Bioscience, Inc. is a contract research and development organization in Morgan Hill, California. Aragen specializes in recombinant cell line and hybridoma development, cell culture and protein purification process development and protein production, primary and immortalized cell-based assays, in vivo models of human disease and custom immunological services.

Contacts:
Rick Srigley
CEO
Aragen Bioscience, Inc.
380 Woodview Avenue
Morgan Hill, CA 95037
USA
Tel.: +1 408-779-1700
Fax: +1 408-779-1711
rsrigley@aragenbio.com
www.aragenbio.com

Wolfgang Kintzel
CCO / Geschäftsführer
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Straße 62
D-51105 Köln
Germany
Tel. : +49 (0) 221-46 02 08 – 00
Fax : +49 (0) 221-46 02 08 – 01
kintzel@cevec-pharmaceuticals.com
www.cevec-pharmaceuticals.com

CAP and CAP-T are trademarks of CEVEC Pharmaceuticals GmbH, all rights reserved.
 

Inno Biologics and CEVEC Sign License Agreement for Human CAP Technology

Cologne, Germany, December 08, 2009 / b3c newswire – The developer of a novel human expression system derived from amniocytes “CEVEC Pharmaceuticals” and the contract manufacturer Inno Biologics Sdn Bhd, Malaysia, announced today the signing of a strategic license agreement. This license enables Inno Biologics to offer the full potential of production of their diagnostic and preclinical grade material in highest quality with authentic human glycosylation patterns using the novel and proprietary CAP expression system.
For more information please download PDF.

application/pdf iconCEVEC_Inno.pdf

CEVEC Raises €4M to Finance Strong Growth of Human CAP Technology

Cologne, Germany, November 03, 2009 / b3c newswire – CEVEC Pharmaceuticals, specializing in the development of complex therapeutic proteins based on the human CAP® Technology, today announced the closing of a €4M financing round. Creathor Venture Fonds and NRW.BANK led this round which included the participation from current investors and a group of private and institutional investors including the venture capital branch of Sparkasse KoelnBonn, and ERP Startfonds of KfW bank, both Germany. The funding provides CEVEC with adequate means to continue the global commercialization of the proprietary CAP Technology platform.
For more information please download PDF.

application/pdf iconCEVEC_A4-download-news0911.pdf